

Cortellis clinical trial database Phase II trial summary statistic tables and figures

March 20, 2017

Table 1: Number of Phase II trials receiving NIH funding by presence of biomarker

	No funding	NIH funding	Total
No biomarker	25,511	815	26,326
Biomarker	15,480	785	16,265
Total	40,991	1,600	42,591

Table 2: Number of Phase II trials receiving NIH funding by presence of biomarker

	(1) All Trials	(2) US Trials	(3) Non-US Trials
Number of trials receiving funding			
No biomarker	815 (28.1)	769 (26.6)	46 (6.8)
Biomarker	785 (27.3)	739 (25.8)	46 (6.8)
Percent of trials receiving funding			
No biomarker	3.1 (0.11)	7.7 (0.27)	0.3 (0.04)
Biomarker	4.8 (0.17)	9.7 (0.34)	0.5 (0.08)
Observations	42591	17590	25001

Table 3: Percent of Phase II trials receiving NIH funding by biomarker type

	(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Genomic	Proteomic	Biochemical	Cellular	Physiological	Structural	Anthropomorphic
Percent of trials receiving funding	5.6 (0.2)	5.4 (0.2)	4.2 (0.3)	7.1 (0.5)	2.2 (0.2)	3.8 (0.6)	2.6 (0.5)
Observations	10850	11314	4732	2650	4238	1221	1210

Standard errors in parentheses

Table 4: Percent of Phase II trials receiving NIH funding by biomarker role

	(1)	(2)	(3)	(4)
	Disease	Therapeutic effect	Toxic effect	Not determined
Percent receiving funding	6.3 (0.4)	5.0 (0.2)	2.2 (0.4)	2.9 (2.1)
Observations	3795	13267	1394	68

Standard errors in parentheses

Table 5: Trials by Phase

	Trial count	Percent of all Phase II
Phase 2 Clinical	39,482	92.7
Phase 2a Clinical	1,768	4.2
Phase 2b Clinical	1,341	3.1
Total	42,591	100.0

Table 6: Selected statistics by NIH funding status

	No NIH funding		NIH funding	
	Mean	# of nonmissing observations	Mean	# of nonmissing observations
Duration	37.4	28,834	58.4	1,268
US Trial	0.39	40,991	0.94	1,600
Subjects enrolled	105.9	39,184	72.4	1,499

Table 7: Average trial duration in months

Year	Duration	# of trials with nonmissing duration
1995	69.6	96
1996	79.3	115
1997	63.1	207
1998	61.9	283
1999	59.4	429
2000	59.4	497
2001	55.7	634
2002	49.7	852
2003	48.8	1,087
2004	45.4	1,397
2005	40.7	1,766
2006	40.7	1,965
2007	37.7	2,205
2008	35.7	2,273
2009	37.3	2,414
2010	34.9	2,311
2011	34.3	2,336
2012	32.7	2,352
2013	32.5	2,351
2014	30.1	2,189
2015	30.7	2,343
Observations	30102	

Table 8: Percent of Phase II trials receiving NIH funding by presence of biomarker: All trials

	(1)	(2)
	No biomarker	Biomarker
1995	6.0	3.4
1996	4.2	7.7
1997	7.3	10.0
1998	5.3	9.1
1999	6.1	15.1
2000	5.5	9.0
2001	4.6	10.9
2002	4.1	8.9
2003	3.5	6.3
2004	4.9	7.2
2005	4.2	7.4
2006	3.0	8.4
2007	2.5	6.7
2008	2.9	4.9
2009	2.5	4.7
2010	1.3	4.1
2011	1.2	3.5
2012	1.1	2.9
2013	2.1	3.8
2014	1.8	2.9
2015	2.6	3.4

Table 9: Percent of Phase II trials receiving NIH funding by presence of biomarker: US trials

	(1)	(2)
	No biomarker	Biomarker
1995	18.4	5.0
1996	11.4	8.7
1997	16.7	14.3
1998	10.9	10.9
1999	10.7	18.5
2000	11.7	11.9
2001	8.9	17.1
2002	9.2	13.2
2003	8.2	10.0
2004	10.5	12.2
2005	10.3	13.2
2006	7.4	15.5
2007	6.6	13.2
2008	6.9	9.3
2009	5.8	9.5
2010	4.0	8.2
2011	3.2	7.8
2012	3.8	6.9
2013	6.4	8.5
2014	4.6	5.8
2015	6.9	7.9



